Being Prepared for Questions on Direct-To-Consumer Preemptive Pharmacogenomic Testing

<p>Mackenzie L. Bevry, PharmD, identifies the key populations that currently have evidence for improved outcomes with pre-emptive pharmacogenomic testing, describes the difference between clinical and direct-to-consumer pharmacogenomic testing, recognizes some of the currently available pharmacogenomic testing options available to patients.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>